Directorate Change

November 17, 2015 9:01 AM ET

17 November 2015

LIVANOVA PLC

LivaNova PLC (the "**Company**" or "**LivaNova**"), a leading global medical technology company, announces that Rosario Bifulco, a member of the Company's board of directors has resigned as a director effective immediately.

Dan Moore, Chairman of LivaNova, remarked: "We would like to thank Rosario for his many contributions to LivaNova, and previously to Sorin. We wish him the very best in his new endeavors". Concurrently with his resignation from the Company's board of directors, Mr. Bifulco has assumed the role of Chief Executive Officer of Mittel S.p.A.

The Company's Nominating & Corporate Governance Committee will immediately initiate a process for the appointment of a successor.

- End -

About LivaNova

LivaNova PLC, headquartered in London, U.K., is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK's Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol "LIVN".

For more information, please visit www.livanova.com, or contact:

Investor Relations: Vivid Sehgal Chief Financial Officer e-mail: <u>investor.relations@livanova.com</u> Investor Relations and Media: Greg Browne Senior Vice President, Finance Phone: +1 (281) 228-7262 Fax: +1 (281) 218-9332 e-mail: corporate.communications@livanova.com